These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9215394

  • 1. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.
    Fuerst J, Fiebiger E, Jungwirth A, Mack D, Talwar PG, Frick J, Rovan E.
    Prostate; 1997 Jul 01; 32(2):77-84. PubMed ID: 9215394
    [Abstract] [Full Text] [Related]

  • 2. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.
    Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xia WG, Bosland MC, Murthy KK, Walfield AM, Koff WC, Zamb TJ.
    Vaccine; 2004 Mar 12; 22(9-10):1300-13. PubMed ID: 15003660
    [Abstract] [Full Text] [Related]

  • 3. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.
    Junco JA, Basalto R, Fuentes F, Bover E, Reyes O, Pimentel E, Calzada L, Castro MD, Arteaga N, López Y, Hernández H, Bringas R, Garay H, Peschke P, Bertot J, Guillén G.
    Adv Exp Med Biol; 2008 Mar 12; 617():581-7. PubMed ID: 18497085
    [Abstract] [Full Text] [Related]

  • 4. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
    Junco JA, Peschke P, Zuna I, Ehemann V, Fuentes F, Bover E, Pimentel E, Basulto R, Reyes O, Calzada L, Castro MD, Arteaga N, López Y, Garay H, Hernández H, Bringas R, Guillén GE.
    Vaccine; 2007 Dec 05; 25(50):8460-8. PubMed ID: 18022737
    [Abstract] [Full Text] [Related]

  • 5. Active immunization against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma.
    Ladd A, Walfield A, Tsong YY, Thau R.
    Am J Reprod Immunol; 1995 Sep 05; 34(3):200-6. PubMed ID: 8561879
    [Abstract] [Full Text] [Related]

  • 6. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration.
    Tieva A, Wilkström P, Olofsson JI, Bergh A, Damber JE.
    Prostate; 1999 May 05; 39(2):101-7. PubMed ID: 10221565
    [Abstract] [Full Text] [Related]

  • 7. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
    Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV.
    Endocrinology; 1990 Dec 05; 127(6):3052-60. PubMed ID: 2174343
    [Abstract] [Full Text] [Related]

  • 8. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.
    Hill RE, de Avila DM, Bertrand KP, Greenberg NM, Reeves JJ.
    Exp Biol Med (Maywood); 2003 Jul 05; 228(7):818-22. PubMed ID: 12876301
    [Abstract] [Full Text] [Related]

  • 9. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA, de Voogt HJ, Rao BR.
    Prostate; 1987 Jul 05; 11(3):281-90. PubMed ID: 2960958
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.
    Johnson MP, Thompson SA, Lubaroff DM.
    J Urol; 1985 Jun 05; 133(6):1112-20. PubMed ID: 4039764
    [Abstract] [Full Text] [Related]

  • 11. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
    Wikström P, Bergh A, Damber JE.
    Urol Res; 1997 Jun 05; 25(2):103-11. PubMed ID: 9144876
    [Abstract] [Full Text] [Related]

  • 12. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
    Ichikawa T, Akimoto S, Shimazaki J.
    Endocr J; 1993 Aug 05; 40(4):425-30. PubMed ID: 7522799
    [Abstract] [Full Text] [Related]

  • 13. Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma.
    Toma JG, Amerongen HM, Hennes SC, O'Brien MG, McBlain WA, Buzzell GR.
    J Pineal Res; 1987 Aug 05; 4(3):321-38. PubMed ID: 3625464
    [Abstract] [Full Text] [Related]

  • 14. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
    Brändström A, Westin P, Bergh A, Cajander S, Damber JE.
    Cancer Res; 1994 Jul 01; 54(13):3594-601. PubMed ID: 8012987
    [Abstract] [Full Text] [Related]

  • 15. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
    Sylvester PW, Ip MM.
    Prostate; 1987 Jul 01; 10(1):57-67. PubMed ID: 3822918
    [Abstract] [Full Text] [Related]

  • 16. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
    Redding TW, Coy DH, Schally AV.
    Proc Natl Acad Sci U S A; 1982 Feb 01; 79(4):1273-6. PubMed ID: 6803239
    [Abstract] [Full Text] [Related]

  • 17. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
    Dijkman GA, Van Moorselaar RJ, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FM, Schalken JA, de Coster R.
    J Urol; 1994 Jan 01; 151(1):217-22. PubMed ID: 8254818
    [Abstract] [Full Text] [Related]

  • 18. Semisynthetic anti-LHRH vaccine causing atrophy of the prostate.
    Jayashankar R, Chaudhuri MK, Singh O, Alam A, Talwar GP.
    Prostate; 1989 Jan 01; 14(1):3-11. PubMed ID: 2648346
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 20. The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines.
    Diamond DA, Barrack ER.
    J Urol; 1984 Oct 01; 132(4):821-7. PubMed ID: 6471235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.